Corient Private Wealth
INTS icon

Corient Private Wealth’s Intensity Therapeutics INTS Stock Holding History

Corient Private Wealth’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,000
Closed -$41K – 2918
2025
Q4 		$41K Buy
+4,000
New +$40.6K ﹤0.01% 2608

Other funds holding INTS

KCIA
Kingsbury Capital Investment Advisors Wilmette, Illinois $118M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Corient Private Wealth's INTS Position: Q1 2026 in Review

Corient Private Wealth sold out of Intensity Therapeutics (INTS) in Q1 2026, closing a stake of 4,000 shares — an estimated $41K sold.

Corient Private Wealth first reported a position in INTS in Q4 2025 and held it in 1 quarter. The position peaked at $41K in Q4 2025. 14 funds tracked by Wall St. Rank hold INTS as of Q1 2026.

  • Corient Private Wealth reported no remaining Intensity Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Corient Private Wealth sold 4,000 Intensity Therapeutics shares in Q1 2026, an estimated $41K.
  • Corient Private Wealth first reported a position in Intensity Therapeutics in Q4 2025 and held it in 1 quarter.
  • Corient Private Wealth's Intensity Therapeutics position peaked at $41K in Q4 2025.
  • 14 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.